Page 2 - Europe Clinicaltrials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anteris Technologies lauds second successful implant procedure for innovative transcatheter aortic valve

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is celebrating the successful implantation of its new class of biomimetic valves, the world’s only.

British columbiaUnited statesEurope clinicaltrialsJanar sathananthanChris medurWayne patersonHealth canadaAnteris technologies ltdHealth canada special access programSpecial access programVancouver generalEarly feasibility studiesNorth american

DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

BRISBANE, Australia & MINNEAPOLIS (BUSINESS WIRE) Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that DurAVR™ THV, a new class of biomimetic heart valve and

United statesBritish columbiaJanar sathananthanWayne patersonDejan torackiEurope clinicaltrialsMalini chatterjeeChris meduriAnteris technologies ltdCorporate developmentHealth canada special access programHealth canadaBlueprint life science groupSpecial access programVancouver generalAnteris technologies

MedAlliance SELUTION SLR is the First DEB to Receive Coronary de novo IDE Approval, its Fourth FDA IDE DEB Approval

MedAlliance SELUTION SLR is the First DEB to Receive Coronary de novo IDE Approval, its Fourth FDA IDE DEB Approval
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United statesGeorgetown universityDistrict of columbiaRon waksmanEurope clinicaltrialsCardiovascular research at medstar heartVascular instituteMedalliance coronary study steering committeeProfessor of cardiology at georgetown universityDevice exemptionIn stent restenosisCardiovascular researchMedstar heartMedalliance coronary study steeringMiddle east

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval - read this article along with other careers information, tips and advice on BioSpace

United statesGeorgetown universityDistrict of columbiaSwitzerland generalRon waksmanEurope clinicaltrialsCardiovascular research at medstar heartVascular instituteMedalliance coronary study steering committeeProfessor of cardiology at georgetown universityDevice exemptionIn stent restenosisCardiovascular researchMedstar heartMedalliance coronary study steeringMiddle east

Business News | MedAlliance SELUTION SLR is the First DEB to Receive Coronary De Novo IDE Approval, Its Fourth FDA IDE DEB Approval

Get latest articles and stories on Business at LatestLY. SELUTION SLR™, MedAlliance s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. Business News | MedAlliance SELUTION SLR is the First DEB to Receive Coronary De Novo IDE Approval, Its Fourth FDA IDE DEB Approval.

United statesGeorgetown universityDistrict of columbiaSwitzerland generalEurope clinicaltrialsFatima sana shaikhCardiovascular research at medstar heartVascular instituteMedalliance coronary study steering committeeProfessor of cardiology at georgetown universityDevice exemptionIn stent restenosisFatima sana shaikh birthdayHer best fashion appearancesView picsCardiovascular research